Expansion Decisions Require Independent Intelligence
Clinical trial expansion into new geographies introduces operational uncertainty and significant capital exposure.
Novitalis provides structured intelligence designed to support expansion decisions before CRO execution begins
- Enrollment realism modeling
- Competitive trial landscape analysis
- Site reliability scoring
- Capital exposure landscape analysis
India Expansion Is a Capital Allocation Decision — Not an Operational Task
While India offers a strong clinical research capacity, expansion decisions often rely on feasibility assumptions that may not fully reflect real-world enrollment dynamics.
Sponsors must evaluate how protocol complexity, site productivity variability, regulatory timelines, and screening failure rates may influence trial performance.
The Novitalis Clinical Expansion Intelligence Framework
Enrollment Realism Engine
Scenario-based modeling stress-testing enrollment projections against real-world dynamics.
Site Reliability Index
Structured scoring of investigator capability, site infrastructure, and historical performance.
India Trial Risk Index
Multi-domain assessment covering enrollment volatility, regulatory exposure, and capital sensitivity.
Is India Expansion the Right Move for Your Trial?
Before committing capital to new geographies, oncology sponsors often face critical uncertainties.
Novitalis helps answer questions such as:
- Are CRO enrollment projections realistic for India?
- Which sites are truly reliable?
- How will screening failure rates impact timelines?
- What is the capital exposure if recruitment slows?
- Should expansion be approved now or delayed?